Experienced in DICER1 Syndrome

Dr. Lida A. Mina

Mayo Clinic Arizona
Phoenix, AZ
Experienced
in DICER1 Syndrome
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Lida Mina is a Hematologist Oncology specialist and an Oncologist in Phoenix, Arizona. Dr. Mina and is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Mina is currently accepting new patients.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in IN
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Sanford Health
  •  Cigna
  •  Humana

Locations

MAYO CLINIC ARIZONA
5777 E Mayo Blvd, Mayo Clinic Hospital, Phoenix, AZ 85054
800-603-0558
Other Locations
MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259
480-301-8000
MAYO CLINIC ARIZONA
5701 E Mayo Blvd, Phoenix, AZ 85054
480-342-4200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors
Enrollment Status: Completed
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Abraxane
Study Phase: Phase 1/Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, Cisplatin
Study Phase: Phase 2
Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer
Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Procedure
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
Enrollment Status: Completed
Publish Date: March 30, 2018
Intervention Type: Drug, Other
Study Phase: Early Phase 1
View 8 Less Clinical Trials

42 Total Publications

Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 26, 2024
Similar Doctors
Expertise in
6
conditions
Dr. Shakeela W. Bahadur
Hematology Oncology | Oncology | Hematology
Expertise in
6
conditions
Dr. Shakeela W. Bahadur
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (10.7 mi)
480-301-8000
Languages Spoken:
English, Farsi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Shakeela Bahadur is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Bahadur and is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Breast Cancer, and Paget Disease of the Breast. Dr. Bahadur is currently accepting new patients.

Expertise in
9
conditions
Dr. Erkut H. Borazanci
Oncology | Gastroenterology
Expertise in
9
conditions
Dr. Erkut H. Borazanci
Oncology | Gastroenterology

Honorhealth Ambulatory

10510 N 92nd St, Fl 2, 
Scottsdale, AZ 
 (6.9 mi)
480-320-1350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erkut Borazanci is an Oncologist and a Gastroenterologist in Scottsdale, Arizona. Dr. Borazanci and is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, and Pancreatoblastoma. Dr. Borazanci is currently accepting new patients.

Expertise in
12
conditions
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
7200 W Bell Rd Bldg A, 
Glendale, AZ 
 (14.8 mi)
623-487-4822
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharon Ondreyco is a Hematologist Oncology specialist and a Hematologist in Glendale, Arizona. Dr. Ondreyco and is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Chronic Lymphocytic Leukemia (CLL). Dr. Ondreyco is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile